Background New research criteria for preclinical Alzheimer's disease have been proposed,
which include stages for cognitively normal individuals with abnormal amyloid markers …

Background A new classification for biomarkers in Alzheimer's disease and cognitive ageing
research is based on grouping the markers into three categories: amyloid deposition (A) …

Summary In 2018, the US National Institute on Aging and the Alzheimer's Association
proposed a purely biological definition of Alzheimer's disease that relies on biomarkers …

Background The biomarker model of Alzheimer's disease postulates a dynamic sequence of
amyloidosis, neurodegeneration, and cognitive decline as an individual progresses from …

Background From the modest but important breakthroughs in the treatment of Alzheimer's
disease (AD), diagnostic focus has increasingly shifted to the accurate detection of the …

Objective To determine the prevalence of preclinical Alzheimer disease (AD) according to
current classification systems by examining CSF from a representative general population …

Background Similar to most chronic diseases, Alzheimer's disease (AD) develops slowly
from a preclinical phase into a fully expressed clinical syndrome. We aimed to use …

Background Improved understanding is needed of risk factors and markers of disease
progression in preclinical Alzheimer's disease. We assessed associations between brain β …

Background Brain amyloid β (Aβ) deposition and neurodegeneration have been
documented in about 50–60% of cognitively healthy elderly individuals (aged 60 years or …

Abstract The Horizon 2020/IMI European Prevention of Alzheimer's Dementia (EPAD)
project will undertake large-scale proof-of-concept trials in predementia Alzheimer's disease …